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INTRODUCTION 
 
 
 
Diabetes mellitus is a group of metabolic diseases or metabolic syndrome where there is 
 
hyperglycemia as a result of defect in the insulin secretion and/or action .In diabetics there is 
 
chronic hyperglycemia which is associated with long-term damage, dysfunction,  
 
and/or failure of various organs, especially the eyes, kidneys, nerves and blood vessels. 
 
 
 
 
 
 
In the cornea, diabetes mellitus has a detrimental or harmful effect on the morphology, 
 
physiology and the clinical appearance. These changes manifest in almost all the layers of  
 
the cornea that is - the corneal epithelium, epithelial basement membrane complexes,  
 
stroma, and the endothelium. 
 
 
 
 
Studies (1–7) (8–12) have looked at the central corneal thickness (CCT) in diabetics. 
 
Many studies have shown increased CCT in diabetics (1–10,12) while few others have  
 
shown no difference in CCT (10) in diabetics as compared to normals.  
 
Changes    in  the  corneal   endothelium  (2,13–15)  and    biomechanical 
 
properties(16),(17) have also been documented. 
 
 
 
 
Relationship of the CCT with the duration of diabetes (6) ,(9), (10), (15) type of  
 
diabetes (18), severity of diabetes (7) ,(9), (10) and HbA1c levels (5), (8) ,(10), (17) have  
 
been studied which have shown varying results. 
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There are very few studies (9)which have looked into changes in CCT in hyperglycemic 
 
state in comparison to euglycemic state in the same individual. 
 
 
 
 
Yasim et al (9) have looked at the variation in CCT in diabetic individuals in euglycemia  
 
and hyperglycemia over 6 months. They defined hyperglycemia and euglycemia based  
 
on the HbA1c levels. However the actual blood sugar levels at the the time of CCT  
 
measurements were not recorded / addressed as a part of the study. 
 
 
 
 
Mc Namara et al (11) have looked at various corneal responses including CCT  
 
in euglycemic and hyperglycemic states which were induced with infusions of dextrose  
 
and insulin. There are no studies which have looked at the CCT in real life situation when  
 
blood sugars vary in diabetic individuals. 
 
 
 
 
It is likely that that the structural and functional changes seen in diabetics is due to the  
 
Effect of chronic hyperglycemia rather than acute variations in blood sugar levels. Though  
 
changes in refraction and lens thickness have been described in hyperglycemic states,  
 
short term changes in CCT in hyperglycemic state has not been studied in diabetics. 
 
 
 
 
Hence we wished to obtain data to see if there is any change in CCT in diabetics during high 
 
blood sugars (hyperglycemic state) and when re -measured in the same individuals when  
 
the sugars were controlled (euglycemic state). 
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Also, CCT has a direct effect on intra ocular pressure (IOP) measurement as measured by  
 
the gold standard method – Goldmann applanation tonometry. IOP is overestimated in  
 
thicker corneas and CCT is underestimated in thinner corneas. IOP measurement is routinely  
 
done in all patients and especially has a role in the management of glaucoma. In the  
 
treatment of glaucoma, studies in glaucoma patients have shown that even 1 mm Hg  
 
lowering of IOP lowers the risk of progression (19). Hence appropriate IOP  
 
estimation is important. 
 
Therefore from our study we also wished to find out if there is a need to know the 
 
hyperglycemic status of an individual while measuring IOP. 
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AIMS 
 
 
To study if there is a change in central corneal thickness in diabetic individuals  
 
in hyperglycemic state in comparison to when the same individuals achieve euglycemic state. 
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OBJECTIVES 
 
 
1. To measure among diabetics, the central corneal thickness (by optical biometry) in 
 
hyperglycemic state and central corneal thickness in the same patients during 
 
euglycemic state after 1 month. The corneal thickness will be measured within half an 
 
hour of determining post prandial blood sugar levels. 
 
 
 
 
2. To look for any changes in the corneal thickness with short term variation (1 month)  
 
   in blood sugars as measured during hyperglycemic and euglycemic state. 
 
 
 
 
3. To study the correlation of change in central corneal thickness if any, with change in 
 
blood sugar levels. 
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REVIEW OF LITERATURE 
 
 
 
Diabetes mellitus, is a chronic metabolic disorder characterised by increased 
 
levels of blood glucose which causes development of micro-vascular and macro- 
 
vascular disorders, leading to functional and morphological changes in several 
 
organs including eye. 
 
 
 
 
 
Diabetes Mellitus 
 
Definition 
 
Diabetes mellitus is referred to a group of metabolic diseases which is characterized 
 
by hyperglycemia resulting from defects in insulin action, secretion or both. (1) 
 
This condition if not controlled is associated with damage of various organs which 
 
includes eyes, heart, nerves, and blood vessels. 
 
 
 
Epidemiology of diabetes mellitus 
 
 
Global 
 
There is a worldwide increase in the incidence of diabetes mellitus reaching epidemic 
 
proportions in developing countries like India, China etc. 
 
As per the WHO global report on diabetes, the worldwide prevalence of diabetes 
 
mellitus among adults has soared from 4.7% in 1980 to 8.5% in 2014. (20) 
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India 
 
In the year 2000, India (31.7 million) had maximum number of people with diabetes 
 
mellitus followed by China (20.8 million) (21) 
 
 
 
 
According to Wild et al. (22) diabetes prevalence is expected to double globally from 
 
171 million in year 2000 to 366 million in year 2030 with a highest increase in India. 
 
There is also a prediction that by year 2030 diabetes mellitus may affect up to 79.4 
 
million people in India, while China (42.3 million) and the United States (30.3 
 
million) will also see increase in those affected by diabetes. (22) (23) 
 
 
 
 
Classification of diabetes mellitus 
 
Diabetes can be classified into the following categories(24) 
 
1. Type 1 diabetes - It is due to β-cell destruction, leading to insulin deficiency. 
 
2. Type 2 diabetes -It is due to a progressive insulin secretory defect and insulin 
 
resistance 
 
3. Gestational diabetes mellitus (GDM) – Diagnosed in the 2nd or in 3rd trimester 
 
of pregnancy, however it is not overt diabetes. 
 
4. Specific types of diabetes such as due to diseases of the exocrine pancreas, 
 
monogenic diabetes syndromes and chemical-induced diabetes 
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Type 2 Diabetes ADA Diagnostic criteria 
 
 
The criteria for the diagnosis of diabetes as per the American Diabetes Association ADA)  
 
criteria are any of the following (25) 
 
 
 
A hemoglobin A1c (HbA1c) level of 6.5% or higher; test performed by a 
 
method that is certified by the National Glycohemoglobin 
 
Standardization Program (NGSP) and standardized to the Diabetes 
 
Control and Complications Trial (DCCT) reference assay. 
 
 
 
 
 Fasting plasma glucose level of 126 mg/dL or higher, when 
 
fasting is defined as no caloric intake for at least 8 hours. 
 
 
 
 
 2-hour plasma glucose level of 200 mg/dL or higher during a 
 
75-g oral glucose tolerance test (OGTT) 
 
 
 
 
 Random plasma glucose of 200 mg/dl or higher with classic symptoms of 
 
hyperglycemia such as polyuria, polyphagia, polydipsia, weight loss or 
 
hyperglycemic crisis. 
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Effects of hyperglycemia on the eye 
 
 
 
Lids/Lashes 
 
Diabetic patients are prone for infection and therefore are at a higher risk of 
 
developing blepharitis (26), orbital cellulitis(27) and recurrent hordeolum (28) . Conjunctiva 
 
Siefart et al did a study which showed that 86% of diabetic individuals had 
 
pathological changes in the conjunctiva (29) 
 
Another study noted an increase in squamous metaplasia and a reduction in 
 
goblet cell density (30), (31). 
 
 
 
 
 
Cornea 
 
 
Various structural as well as physiological changes occur in diabetics and is discussed 
 
separately in detail subsequently. 
 
 
 
 
 
Iris 
 
Neovascularization is one of the most detrimental effect on iris. It is frequently present 
 
around the pupillary margin but in advanced cases, it can involve the anterior chamber 
 
angle and the entire iris (32).These changes lead to neovascular glaucoma. 
 
 
There is depigmentation of the iris epithelium which causes release of pigments (33). 
 
 
 
17 
 
 
 
Pupil 
 
Diabetic individuals exhibit small pupil with normal light reflexes because the 
 
sympathetic innervation is affected(34). Preferential loss of nerve terminals from the 
 
dilator muscle was seen on histological studies of irides. (35) This can lead to 
 
difficulties during surgery and more manipulations of the pupil during surgery leading 
 
to excessive post operative inflammation. 
 
 
 
 
 
Changes in refraction and lens 
 
 
 
 
 
Furushima et al (36) did a study in Otia, Japan to determine changes in refraction 
 
caused by the induction of acute hyperglycemia in healthy subjects .They wanted to 
 
find out whether the ocular hypotension and myopic changes after a load of glucose 
 
are caused by hyperglycemia. Oral glucose tolerance tests were carried on 7 healthy 
 
young volunteers with normal vision. Hematologic parameters and the refractive 
 
system changes were measured after the glucose load periodically for 150 minutes . 
 
 
 
 
 
 
After the glucose load a hike was noted in the plasma glucose level and of plasma 
 
osmosis level, ocular hypotension, a myopic change in refractive power and lens 
 
thickening. Degree of the myopic change surpassed the power of residual 
 
accommodation. Normalisation of the plasma glucose level led to a normalisation of 
 
the intraocular pressure and a reversal of the myopic changes. These findings propose 
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that the myopic changes that associate with hyperglycemia were caused by lens 
 
thickening, resulting from a reduction in the tension of the zonule fibers of Zinn, and 
 
were secondary to the ocular hypotension. The reversal of the myopia after 
 
normalization of plasma glucose levels appeared to cause hyperopia. 
 
 
 
 
Wiemer et al, did report an effect of diabetes on the refractive power of the posterior 
 
cornea ; since this change did not affect total corneal power, it remains most likely 
 
that the refractive changes seen in diabetics is due to lens changes(37) 
 
 
 
 
 
 
Diabetic patients have a higher risk for early onset cataracts . 
 
 
 
 
Many large population studies such as Blue Mountains Eye Study (38) 
 
and Beaver Dam Eye Study (39), have reported increased prevalence and incidence 
 
of posterior subcapsular cataracts in diabetic patients. 
 
 
 
 
 
 
 
 
The hypotheses that favour and explain diabetic complications in the lens and 
 
affected organs are (40) 
 
 
1. Aldose reductase mediated increased flux throught the polyol pathway is the 
 
first mechanism 
 
2. Glucose mediated activation of a specific isoform of protein kinase C is the 
 
second mechanism that leads to early cataract in diabetics. 
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3. A third mechanism is the production of increased amounts of advanced 
 
glycation end products (AGEs).AGEs are produced by the non-enzymatic 
 
reaction of aldehydes, like glucose, with a wide variety of chemical species. 
 
 
 
Diabetics and animals with experimental diabetes accumulate increased levels of 
 
AGEs in connective tissues and within cells. Treatments that block each of these three 
 
biochemical pathways have been shown to reduce or prevent diabetic 
 
complications in one or more experimental systems. 
 
 
 
 
 
Aqueous humor 
 
Effect of diabetes on aqueous humor dynamics has not been consistent according to 
 
reports While some studies suggested that diabetics exhibit a reduced rate of aqueous 
 
formation (41) (42) others have found this hyposecretion to be mild and not clinically 
 
significant (43) 
 
 
Vitreous 
 
 
There is abnormal collagen crosslinking and also non-enzymatic glycation (44) which 
 
is found to occur in the vitreous of diabetic individuals leading to precocious vitreous 
 
liquefaction and posterior vitreous detachment (PVD) (45), (46) 
 
 
 
 
 
 
Retina 
 
 
Diabetes mellitus cause retinopathy where there is microangiopathy in which the 
 
small vessels become vulnerable to damage from hyperglycemia .Also hyperglycemia 
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directly effects the retinal cells. 
 
 
1. There are several mechanisms of cellular death which include accumulation of 
 
sorbitol intracellularly, radical excess causing oxidative stress, advanced glycation end 
 
products and excessive activation of several protein kinase C isoforms.An important 
 
early feature is disruption of ion channel function. 
 
 
 
 
 
 
2. There is also damage of the capillaries characterized by death of pericytes 
 
,capillary basement membrane thickening , vascular smooth muscle cells loss and 
 
endothelial cell proliferation .There are also hemotological changes seen such as 
 
abnormalities of erythrocytes and leucocytes, increased plasma viscosity and 
 
increased platelet adhesion. Because of the above features capillary dysfunction 
 
manifests with leakage and occlusion. 
 
 
 
 
 
 
3. Retinal hypoxia because of capillary non perfusion may lead to neovascularization 
 
extending preretinally and intraretinally which occur as intraretinal microvascular 
 
abnormalities. New vessel growth is thought to be caused by an imbalance between 
 
the elaboration of angiogenic and anti – angiogenic factors, in an attempt to 
 
revascularize hypoxic retina. Many angiogenic stimulators such as vascular 
 
endothelial growth factor, platelet derived growth factor and hepatocyte growth factor 
 
have been identified. 
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Brownlee M (47) also has described in his study on biochemistry and molecular cell 
 
biology of the development of diabetic retinopathy as increased polyol pathway flux, 
 
increased advanced glycation end products (AGEs) formation, activation of protein 
 
kinase C (PKC) isoforms and increased hexosamine pathway flux. 
 
 
 
 
 
 
Diabetic retinopathy is broadly classified into non proliferative and proliferative 
 
diabetic retinopathy. 
 
 
Non proliferative retinopathy is a stage in which there is development of 
 
microaneurysms, dot and blot hemorrhages, exudates and venous changes because of 
 
the various abnormalities as stated below. It is a stage before proliferative diabetic 
 
retinopathy. 
 
 
Proliferative diabetic retinopathy is characterized by formation of new blood vessels 
 
on or within 1 disc diameter of the optic disc and /or new vessels elsewhere in the 
 
fundus.(48) 
 
 
Cornea 
 
 
Both structural as well as physiological changes in the cornea have been well studied 
 
and documented in diabetic patients. The many corneal complications of which 
 
diabetics are at a greater risk include superficial punctuate keratitis, recurrent corneal 
 
erosions, persistent epithelial defects and corneal endothelial damage . (49), (50), (14) 
 
The above mentioned corneal complications have been linked to abnormalities in the 
 
tear secretion, reduced corneal sensitivity ,and poor adhesion between epithelial cells 
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and its basement membrane(49), (51).Changes in the corneal biomechanical properties 
 
as well as the changes in the corneal thickness has also been documented. These 
 
changes are discussed below in detail. 
 
 
 
 
 
 
Cornea has a total of five layers of which the major bulk ( upto 90% of its thickness ) 
 
is made up of stroma which is externally bounded by bowman’s membrane and 
 
epithelium and internally bounded by descemet’s membrane and endothelium. 
 
Cornea is composed of 78% water, 15%collagen, 5%other proteins, 0.7% keratan 
 
sulphate, 0.3%chondroitin sulphate and 1% salts.(52) 
 
 
 
Changes in the epithelium and endothelium 
 
 
Structural changes in corneal epithelial and endothelial cells have been documented 
 
in diabetics. 
 
 
 
 
Taylor et al obtained corneas of 12 eye donors with maturity-onset diabetes and the 
 
corneal epithelial basement membranes were studied by transmission electron 
 
microscopy. Similar tissue was obtained from 12 nondiabetic eye donors who were 
 
matched for age (within 2 years) and race. The mean thickness of the corneal 
 
epithelial basement membrane in nondiabetic patients was 0.33 fim (±0.11 S.D.), 
 
which gives a normal range of 0.11 to 0.55 fim. None of the nondiabetic basement 
 
membranes lay outside this range. The basement membranes of four 
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of the 12 diabetics exceeded this thickness. No race or sex difference was seen in 
 
basement membrane thickness, nor was a clear trend seen with age. Multilaminated 
 
basement membranes were seen in eight diabetic patients and six nondiabetic patients. 
 
Multilamination was more clearly related to basement membrane thickness than to 
 
the presence or absence of diabetes. 
 
 
 
 
 
Choo et al (10)did a hospital based , observational study in which he studied 200 
 
eyes (from 100 type II diabetic patients and 100 controls) were included. Specular 
 
microscopy and pachymetry were used to measure endothelial cell density, size, , 
 
hexagonality, coefficient of variation in cell area as well as corneal thickness. 
 
Endothelial cell density in the diabetic group (2541.6± 516.4 cells/mm2) was 
 
significantly lower than that in the control group (2660.1± 515.5 cells/mm2, <0.05). 
 
The average size of endothelial cells, standard deviation (SD) of cell size and 
 
coefficient of variation (CV) of cell area were all significantly higher in diabetics. 
 
Hexagonality was significantlylower in diabetics (41.1% ± 19.6% ) compared to non- 
 
diabetics (45.2%± 20.6%). CCT was higher in diabetics but not significant ( >0.05). 
 
 
 
 
 
 
Lee et al (15) studied the differences of corneal thickness and corneal endothelial 
 
morphology in diabetes compared with age matched, healthy control 
 
subjects.Ultrasound pachymetry and noncontact specular microscopy were performed 
 
on 200 patients with diabetes and 100 control subjects.Correlation between the subject 
 
parameters and the duration of diabetes was done using a partial correlation 
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coefficient that controlled for age.The diabetic subjects had thicker corneas, less cell 
 
density and hexagonality, and more irregular cell size of the corneal 
 
endothelium than did the controls Central corneal thickness and the coefficient of 
 
variation for cell size were significantly higher for diabetes of over 10 years’ duration 
 
than for diabetes of under 10 years’ duration. 
 
The endothelial cell density and percentage of hexagonal cells were lower for diabetes 
 
of over 10 years’ duration than for diabetes of under 10 years’. CCT was correlated 
 
with duration of diabetes, but corneal endothelial morphology was not . 
 
 
 
 
 
 
Roszkowska etal (53) studied the corneal endothelium in type I and type II diabetic 
 
patients. 75 diabetics divided into type I and type II groups and 62 healthy volunteers 
 
took part in the study. The mean endothelial cell density and morphology, and the 
 
central corneal thickness were evaluated and statistical analysis was done. All 
 
evaluated parameters were found to be significantly different in both diabetic groups 
 
with reduction of the mean cell density of 5% in type II and of 11% in type I diabetes 
 
with respect to the normal age-matched control group. 
 
 
 
 Important alterations of endothelial morphology were observed. The central corneal 
pachymetry wassignificantly higher in diabetics, with p < 0.01 in the type I group and p < 
0.05 in thetype II group. It is concluded that corneal endothelium in diabetics should still be 
 
considered as a tissue under continuous metabolic stress with consequent high 
 
vulnerability, especially in case of any external insult such as a surgical procedure. 
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Busted etal (2) the corneal endothelium was photographed by specular microscopy 
 
in 81 insulin dependent juvenile diabetic outpatients. As revealed in the specular 
 
photomicrographs, minute folds in the endothelial layer were found in 13 of 
 
the diabetics versus 1 of the normal group (2p<0-01). The cell density and the 
 
occurrence of dystrophic changes in the endothelium did not differ from those in 
 
normal persons. The augmented corneal thickness in the diabetic subjects is 
 
tentatively interpreted as minimal corneal swelling. It seemed to be present very early 
 
in the disease and may thus be one of the earliest clinically 
 
detectable changes of the diabetic eye. 
 
 
 
 
 
 
 
Calvo- Maroto et al (8) did a comparative study of 77 eyes of type 2 diabetic 
 
patients (33 males, 44 females) and 80 eyes of healthy subjects (42 males, and 38 
 
females) whose ages ranged from 38 to 56 years. CCT and endothelial cell density 
 
(ECD) , HbA1c levels, and Goldmann tonometry were measured. The CCT was 
 
significantly higher and the ECD significantly lower in long-term diabetic patients 
 
(10 years + since diagnosis) when compared with short-term diabetic patients 
 
(<1 year since diagnosis) and controls (both p < 0.001). No significant differences in 
 
CCT (p = 0.30) and ECD (p = 0.31) were found between control groups. 
 
 
 
 
 
 
 
Schultz et al (14) studied corneas from 25 patients who had had type II (adult-onset) 
 
diabetes for more than ten years were examined by specular microscopy with 
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quantitative morphometric analyses of individual endothelial cells. Thirty-four 
 
corneas from 21 age-matched nondiabetic subjects were examined for comparison. 
 
We also examined 31 corneas from 17 patients with type I (juvenile-onset) diabetes 
 
and compared them to 41 corneas from 23 age-matched normal volunteers. The 
 
corneal endothelium in type II diabetes showed no difference in cell density but 
 
demonstrated a significantly higher coefficient of variation, a decrease in the 
 
percentage of hexagonal cells, and a low figure coefficient compared to an age- 
 
matched nondiabetic population. Type I diabetes produced similar cell changes, but 
 
these changes occurred in the earlier decades. Moreover, we detected a significantly 
 
higher rate of cell loss in type I diabetes, resulting in a significant decrease in cell 
 
density in the fourth and fifth decades. These results clearly indicate that the diabetic 
 
endothelium is morphologically abnormal. The observed anatomic changes result in a 
 
less stable and more vulnerable cell layer, possibly explaining some of the persistent 
 
clinical changes in the diabetic cornea after surgical trauma. 
 
 
 
 
 
 
Keoleian et al- (13)We performed specular microscopy, anterior segment ocular 
 
fluorophotometry, corneal pachymetry, and tonometry on 14 patients with chronic 
 
type I diabetes and nonproliferative retinopathy and on 14 age-matched control 
 
subjects. The eyes of patients with diabetes had an increased coefficient of variation of 
 
endothelial cell area, a decreased percentage of hexagonal endothelial cells, increased 
 
corneal autofluorescence, and increased intraocular pressure, which confirmed 
 
previous studies. There was no difference, however, in corneal thickness or 
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endothelial permeability to fluorescein. Thus, we were unable to detect any 
 
abnormality in endothelial function in these diabetic corneas in the unstressed state, 
 
despite structurally abnormal endothelial cells. 
 
, 
 
 
 
 
Storr Paulsen et al- (5) did a study to determine corneal endothelial cell density and 
 
morphology in type II diabetic and non-diabetic patients and to relate potential 
 
differences to the glycaemic status. It was a prospective clinical study including 
 
107patients with type II diabetes, 128 non-diabetic patients. Sample size was based 
 
on a power calculation(power = 0.90; p = 0.05). The diabetic patients had > four 
 
HbA1c tests performed (mean 4.1; range 2–14) with intervals of at least 3 months 
 
as a reflection of the long-term glycaemic status.. The endothelial cell density, 
 
variation in endothelial cell size (CV), the percentage of hexagonal cells, and the 
 
central cornealthickness (CCT) were recorded .Type II diabetic subjects did not differ 
 
from the normal subjects with regards to endothelial cell density, hexagonality or 
 
variation in CV, but showed a significant increase in CCT (538 versus 546 lm, p < 
 
0.05). In the diabeticgroup, lower cell counts were associated with greater HbA1c 
 
values (p < 0.05). The HbA1c did not, however, have any impact on the CCT. 
 
Conclusion: Type II diabetes has no impact on corneal cell density or morphology 
 
in subjects with good glycaemic status. However, higher HbA1c was associated 
 
with lower endothelial cell density. CCT was significantly increased in the diabetic 
 
group. 
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Sudhir et al- (54)did a study in which patients were recruited from the Sankara 
 
Nethralaya’s Diabetic Retinopathy Epidemiology and Molecular Genetic Study, a 
 
population-based study to estimate the prevalence of type 2 diabetes and diabetic 
 
retinopathy in Chennai, South India. Corneal endothelial morphological features were 
 
recorded in all subjects using noncontact specular microscopy and central corneal 
 
thickness was measured using ultrasound pachymeter.Total of 1191 cases and 121 
 
controls were enrolled into the study. Mean corneal endothelial cell density was lower 
 
in cases than in controls (2550 ± 326 vs. 2634 ± 256; P = 0.001). No difference was 
 
found in the mean pachymetry values, hexagonality %, and coefficient of variation of 
 
cell size between cases and controls..Results of study from a large population-based 
 
data, support the theories of lower endothelial cell counts among subjects with type 2 
 
diabetes mellitus in comparison with nondiabetic controls. 
 
 
 
 
 
 
 
Changes in corneal stroma 
 
Several ion transport systems have been postulated to be existing in the corneal 
 
endothelium which helps in maintaining the deturgescence of the corneal stroma via 
 
metabolic energy dependent process.These ion transport systems are Na
+
- K
+
- 
 
ATPase, carbonic anhydrase and bicarbonate ions systems which are essential 
 
for the maintainence of corneal hydration. When the epithelial and endothelial barrier 
 
of the cornea is damaged, the stroma imbibes water and swells. Damage to the 
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endothelium results in hydration of the corneal stroma and increased corneal 
 
thickness.(40) 
 
 
 
 
 
Hyperglycemia induced biochemical processes in the cornea 
 
 
Hyperglycemia is considered to be a major factor in the pathogenesis of diabetes, and 
 
several hyperglycemia-induced biochemical processes have been implicated.(55) 
 
 
 
 
Of particular interest is recent evidence linking elevated glucose to decreased 
 
Na+,K+-ATPase activity in corneal endothelial cells.(56) 
 
 
 
 
Hyperglycemia result in intracellular accumulation of sorbitol which acts as an 
 
osmotic agent which leads to swelling of endothelial cells causing reduction in 
 
endothelial pump function and ATP production.(10) 
 
 
 
 
In vitro studies show that polyhydroxyl compounds (glucose, galactose, galacticol, 
 
sorbitol, or xylitol) inhibit Na+,K+-ATPase activity in cultured bovine corneal 
 
endothelial cells,
16
whereas in vivo studies show reduced Na+, K+-ATPase activity in 
 
the corneal endothelium of diabetic rabbits after only 10 weeks of alloxan-induced 
 
hyperglycemia.(57), (58) 
 
 
 
 
Because this enzyme is a major component of the endothelial fluid pump, it is not 
 
surprising that these same diabetic rabbits also had greater baseline corneal 
 
thickness, decreased corneal swelling response, and slower recovery from hypoxic 
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edema than did non diabetic rabbits.(16) 
 
 
 
 
 
Long term corneal structural changes due to hyperglycemia 
 
Hyperglycemia associated with diabetes can result in increased protein 
 
glycosylation , creating advanced glycosylation end products (AGEs).(17) Studies 
 
have shown increased levels of AGEs in corneas of older diabetics . Increased AGEs 
 
in tissues lead to an increase in collagen cross linkage which results in gradual 
 
stiffening of corneal structure leading to changes in the biomechanical properties of 
 
the cornea.(59) However its contribution to changes in corneal thickness has not been 
 
separately studied. 
 
 
 
 
It has been shown that abrupt correction of hyperglycemia in diabetics can 
 
result in refractive changes in the eye attributable to changes in the function and 
 
morphology of the lens. Zengin et al (60), (61), (62) have proposed that one could 
 
expect that hyperglycemia could affect corneal hydration as well and cause 
 
qualitative and quantitative corneal changes such as refractive index, curvature and 
 
thickness. 
 
 
 
 
 
31 
 
 
 
Corneal biomechanical changes in diabetics 
 
Corneal hysteresis gives an idea about the viscosity of the cornea, thus it reflects the 
 
changes in the corneal stromal collagen organization whereas corneal resistance 
 
factor is associated with the stiffness of cornea. 
 
 
 
 
 
Kotecha et al (63) did a study on corneal thickness- and age-related biomechanical 
 
properties of the cornea measured with the Ocular Response Analyzer . The Ocular 
 
Response Analyzer (ORA) is a new instrument that measures the corneal 
 
biomechanical response (corneal hysteresis, CH) to rapid indentation by an air jet. CH 
 
is the difference in applanation pressures (P1, P2) between the rising and falling 
 
phases of the air jet. The investigation had two parts: a characterization study and a 
 
validation study. In the characterization study, the purposes were to investigate the 
 
intraocular pressure (IOP)–dependence of CH and to characterize the performance of 
 
the ORA. In the validation study, the purposes were to investigate the association 
 
between CH and both age and central corneal thickness (CCT) and the agreement 
 
between ORA and Goldmann applanation tonometer (GAT) IOP measurements. 
 
 
For the characterization study, data were collected from 105 untreated subjects (45 
 
ocular hypertensive patients and 60 normal subjects; mean age, 60 years, range, 26– 
 
82). GAT and ORA measurements were performed before and after IOP lowering of 
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one randomly selected eye with apraclonidine drops. The change in P1 and P2 
 
(arbitrary units) in relation to change in GAT IOP was analyzed to calibrate the 
 
instrument. The relation between P1, P2, and CCT was explored and ORA IOP was 
 
derived from the analyses. For the validation study, ORA and GAT IOP and CCT 
 
were measured in 144 eyes of 144 untreated subjects (mean age, 58 years; range, 19– 
 
83). The characterization calculations were applied to the dataset and values of CH 
 
and ORA IOP were calculated. The relationship between CH and both subject age and 
 
CCT was determined. The associations between CH and CCT and between ORA and 
 
GAT IOPs, were investigated by linear regression analysis. The agreement between 
 
measuring devices was calculated.In the characterization study, P1 changed by 6.41 
 
arbitrary units for every 1-mm Hg change in GAT IOP. CH (P1 − P2) changed by 
 
−1.60 arbitrary units for every 1-mm Hg change in GAT IOP. For each unit change in 
 
P2, P1 changed by 1.27 units. From this association a new IOP-independent corneal 
 
factor was derived [P1 − (P2/1.27)] and is termed the corneal constant factor (CCF; 
 
mm Hg). ORA IOP normalized for CCF was defined as P2 – CCF (mm Hg). The CCF 
 
(mm Hg) was associated with CCT (micrometers) and with age: CCF = [(0.036 · 
 
CCT) − (0.028 · age)] + 1.06 (adjusted r 2 = 0.34; P < 0.0001 for CCT, P = 0.007 for 
 
age). Normalized ORA IOP measurements were not associated with CCT. GAT IOP 
 
was associated with CCT and CCF—more strongly with the latter: GAT IOP = (0.03 · 
 
CCT)+1.52 (r 
2 
= 0.06, P = 0.002); GAT IOP = (0.65 · CCF) + 4.5 (r 
2 
= 0.13, P < 
 
0.0001). The mean difference (95% limits of agreement) between GAT and 
 
normalized ORA IOP was 0.1 (−6.6 to +6.8) mm Hg. The CCF describes an IOP- 
 
independent biomechanical property of the cornea that increases with thicker CCT and 
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decreases with greater age. It is moderately strongly associated with CCT and yet 
 
explains more of the interindividual variation in GAT IOP than does CCT. 
 
Normalized ORA IOP measurements are not associated with CCT. 
 
 
 
 
 
 
 
 
 
 
Scheler et al (16) did a study on 35 healthy individuals and 31diabetic patients to 
 
find out whether corneal resistance factor (CRF) and corneal hysteresis (CH) are 
 
affected in diabetes and whether these parameters are related to HbA1c. Patients with 
 
diabetes were divided into group 1 with HbA1c <7% (n = 14) and group 2 with 
 
HbA1c ‡7% (n = 17). CH and CRF were measured using ocular response analyzer 
 
(ORA) 
 
It was found that in uncontrolled diabetic patients ,CH and CRF are significantly 
 
higher compared with those of the healthy subjects and patients with 
 
well-controlled diabetes. And also there was a correlation of these parameters with 
 
HbA1c suggesting that the biomechanical properties of the cornea are altered based on 
 
the glucose control 
 
. 
 
. 
 
 
Yazgan et al (17) studied biomechanical parameters of cornea in 156 diabetic and 74 
 
healthy eyes using ocular response analyser. Subjects were divided into three groups: 
 
Group 1, healthy control subjects; Group 2, diabetes patients with HbA1C <7%; and 
 
Group 3, diabetes patients with HbA1C >7% It was noted that both the diabetes 
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groups were affected in relation to corneal biomechanical properties when compared 
 
to healthy individuals 
 
 
 
 
 
 
Herse et al(57) showed reports of increased corneal thickness and altered endothelial 
 
morphology suggest that there is abnormal corneal hydration control in diabetic 
 
patients. 
 
 
 
 They studied the possible influence of hyperglycemia on corneal hydration 
 
control, experiments were done on normal and alloxan-induced diabetic rabbits to 
 
assess: 
 
 (1) stromal dry weight, hydration, and swelling pressure;  
 
 
(2) corneal thickness  and contact lens-induced edema recovery responses; and (3) 
endothelial homogenate sodium/potassium adenosinetriphosphatase (Na+/K+ ATPase) 
activity. The data showed that 10 weeks of uncontrolled hyperglycemia in the rabbit results 
in abnormal corneal hydration control indicated by increased corneal thickness, increased 
stromal hydration, and a decreased ability to recover from contact lensinduced 
 
corneal edema. The stroma appeared to be minimally involved in these changes; 
 
swelling pressures and dry weights of the normal and diabetic stroma were not 
 
significantly different. The measured decrease in diabetic rabbit endothelial 
 
homogenate Na+/K+ ATPase activity strongly suggests that endothelial fluid pump 
 
dysfunction is a major component in the abnormal corneal hydration control found in 
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the uncontrolled diabetic rabbit 
 
 
 
 
 
Corneal metabolic and permeability changes in diabetics 
 
 
 
Keoleian et al (13) did a study on on 14 patients with chronic type I diabetes and 
 
nonproliferative retinopathy and on 14 age-matched control subjects on structural and 
 
functional studies of the corneal endothelium in diabetes mellitus. They performed 
 
specular microscopy, anterior segment ocular fluorophotometry, corneal pachymetry, 
 
and tonometry.  
 
 
 
 
 
 
The eyes of patients with diabetes had an increased coefficient of 
 
variation of endothelial cell area, a decreased percentage of hexagonal endothelial 
 
cells, increased corneal autofluorescence, and increased intraocular pressure. There 
 
was no difference, however, in corneal thickness or endothelial permeability to 
 
fluorescein. Thus, were unable to detect any abnormality in endothelial function in 
 
these diabetic corneas in the unstressed state, despite structurally abnormal endothelial 
 
cells. 
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Larsson et al (18) studied 49 patients with type I diabetes mellitus and 60 patients 
 
with diabetes mellitus type II who were recruited from Mayo Clinic, Rochester, 
 
Minn. Controls were the 31 normal subjects, divided by age into 2 groups. 
 
Fluorophotometry,was used to measure corneal endothelial permeability and corneal 
 
autofluorescence. Neither type I nor type II diabetics were different from their 
 
control groups in endothelial permeability and cell density.  
 
 
 
 
 
Pleomorphism, polymegethism increased corneal thickness, and increased corneal  
 
 
autofluorescence was found in type 1 diabeticsas compared with their controls. . The  
 
 
severity of retinopathy was significantly correlated only with corneal autofluorescence.The 
 
 
corneas of patients with type I diabetes mellitus exhibited abnormalities in endothelial 
 
cell morphologic characteristics and corneal autofluorescence. They found no 
 
abnormalities in endothelial permeability in either type I or type II diabetics. 
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Corneal thickness (CCT) in diabetics 
 
 
 
Central corneal thickness has been studied in diabetics. (1), (2), (3), (4), (5), 
 
(7),(8),(9),(10),(11) ,(12). CCT is an important parameter which affects IOP 
 
measurement and has also now come to be recognized as an independent risk factor 
 
for glaucoma. Thick CCT tends to overestimate IOP and thin CCT tends to 
 
underestimate IOP(64) . CCT has been studied in diabetes as well as in glaucoma. 
 
 
 
 
Definition of a normal central corneal thickness 
 
 
A cornea is considered thin or thick depending on the definition of ―normal‖ or 
 
―average‖ central corneal thickness (CCT). 
 
 
 
 
 
 
 
 
 
Clinical application 
 
A meta-analysis by Doughty and Zaman (65) showed that a 10% change in CCT may 
 
result in an approximately 3.4 mm Hg change in intraocular pressure. Moreover, there 
 
is evidence supporting that CCT is an independent risk factor for the development and 
 
progression of glaucoma (66) 
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CCT in various populations 
 
 
Studies which have measured CCT from different populations without any corneal 
 
pathology provide guidance. 
 
Mean CCT for specific populations lie between 510 - 560 microns with 
 
majority being closer to 530-550 microns. Thinnest mean CCT is reported in 
 
central/southern Indians(67),(68) 
 
, Japanese, Australian Aborigines ,North and west Africans, African Americans. The 
 
thickest mean CCT is found in European, White American and Latino populations. 
 
(69), (70), (71), (72), (73), (74), (75), (76), (77), (78), (79), 
 
 
 
 
 
 
 
Most common method to study CCT is ultrasound pachymetry which shows good 
 
repeatability and reproducibility however specular microscopy, SD- OCT ,optical 
 
biometry have been used. 
 
 
 
 
 
 
Comparison of optical and ultrasound pachymetry 
 
 
S Korah et al(80) did a study at Schell Eye Hospital , CMC, Vellore on comparison of 
 
optical and ultrasound pachymetry . The CCT was measured with Haag-Streit 
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slitlamp using the pachymeter attachment no. 1 (Haag Streit AG, Koeniz, 
 
Switzerland). It is suggested that the accuracy of optical pachymeter readings using 
 
the Haag-Streit attachment no. 1 can be increased by correcting for the corneal 
 
curvature .Keratometric readings were obtained using the Bausch & Lomb 
 
keratometer (Rochester, NY, USA). These values were converted to the radius of 
 
corneal curvature and used to correct the optical pachometry measurements. 
 
The mean difference between CCT using the two instruments was 0.001mm, with a 
 
standard deviation of 0.031mm. The standard error of the difference was 0.00439mm. 
 
The calculated range of mean difference ± 2SE is -0.00778 to +0.00878. This includes 
 
zero. The mean difference ± 2SD was-0.062 to + 0.063. If used to "correct" IOP, this 
 
would represent a range of -4.4 mmHg to +4.5 mmHg. 
 
The above results suggested a fair agreement between the optical and ultrasound 
 
pachometry. 
 
 
 
 However, two standard deviations of the difference in CCT, translates to 
 
IOP difference of -4.4 mmHg to +4.5 mmHg, this is not clinically insignificant. 
 
Depending on the clinical situation, this range may or may not be acceptable. Further, 
 
as the error was random, it probably cannot be improved upon. 
 
 
 
 
 
b. Optical pachometry values after correcting for radius of corneal curvature 
 
In this study the mean CCT was 0.538 ± 0.031mm. The value after correcting for the 
 
radius of curvature was practically the same (0.538 ± 0.034mm). The difference was 
 
not significant. 
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In order to determine which of the two methods would be the more reproducible 
 
(reliable) for clinical use, they studied the intra and inter observer variability for both 
 
the instruments. In this study, both the instruments showed an equally low intra- 
 
observer variability [mean difference optical: 0.003mm(SD 0.017) vs ultrasound: 
 
0.002mm (SD 0.011). This is not surprising since the same observer would be 
 
expected to use the same technique and measuring conditions for every patient. 
 
 
 
 
 
 
 
In measurement of the inter-observer variability that of ultrasound pachometry was 
 
low (mean difference 0.001 ± 0.009mm). It was unacceptably high for the optical 
 
method (0.019 ± 0.049mm). There may be many explanations such as- 
 
 
(a) There may have been a difference in the thickness of the optical section used by 
 
the two observers. The optics of the Pachometer 1 instrument are such that the 
 
readings of corneal thickness are most accurate when the optical section used for the 
 
measurement is infinitely thin.(81)It is best to use the thinnest, brightest image for 
 
clear visualization and measurement. Any variation in this thickness could lead to 
 
error. 
 
 
 
 
(b) Inclusion of the tear film in the measuring process is another potential source of 
 
error. To avoid this, the tear film was lightly stained using a fluorescein strip before 
 
taking the measurements. 
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(c) Use of the "overlap"method by one observer and the "touch" method used by 
 
 
the second observer is yet another possibility; but both observers in this study 
 
 
used the touch method. 
 
 
 
 
 
 
 
Other studies too have found that the ultrasound pachymeter seems to fare better than 
 
 
the optical pachymeter; the optical pachymeter has almost two to three times as much 
 
 
inter-session variability as compared to the ultrasound method.(82),(83),(84)  
 
 
 
 
 
 
 
Ultrasound pachymetry is not without disadvantages. Reproducible alignment at the 
 
same corneal location is essential for comparision of values. The major disadvantage 
 
of the ultrasound pachymeter is that reproducible alignment is more difficult to 
 
achieve than for optical measurements.(85) 
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Optical pachymetry measures central corneal thickness by centering the slit beam over the 
non-dilated pupil; mild eccentric measurements have minimal effect.(86) The Mishima- 
Hedby modification of the optical pachymeter allows even more reliable centration but is 
not available for clinical use.(87) 
 
 
 
 
However, for purposes of "correction" of IOP, ultrasound pachymeter measurements 
 
are obtained from 2-3 mm of the central cornea. The variation of corneal thickness in 
 
the central 2-3mm has been found to be minim(88)al and any effect on the correction 
 
factor should be insignificant. 
 
 
 
 
In conclusion, determination of CCT to correct applanation IOP is more reliable with 
 
the ultrasound pachometer than the Haag-Streit attachment 1. Where more than one 
 
observer is involved in obtaining these measurements, the ultrasound should be the 
 
instrument of choice. However, where only one observer is expected to obtain 
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readings, the optical method may be a reasonable substitute, provided the potential 
 
difference from ultrasound correction is acceptable. 
 
 
 
 
 
Bayhan et al (89) did a study to compare the RTVue spectral optical coherence 
 
tomography (SD-OCT), Sirius Scheimpflug-Placido topographer, Lenstar optical low 
 
coherence reflectometry (OLCR) and ultrasound pachymetry (USP) devices in terms 
 
of their agreement and repeatability of measuring central corneal thickness (CCT).In 
 
this prospective study, 50 eyes of 50 patients were included. Three repeated measures 
 
were obtained using SD-OCT, Scheimpflug-Placido topographer and USP and five 
 
measurements were determined with the OLCR. Bland-Altman plots were used to 
 
assess agreement among the instruments, and 95% limits of agreement (LoA) for each 
 
comparison were calculated. Intra-examiner repeatability was assessed using 
 
intraclass correlation coefficients (ICCs).The mean CCT by SD-OCT, Scheimpflug- 
 
Placido topographer, OLCR, and USP were 525.90±34.08 µm, 525.92±34.10 µm, 
 
530.30±35.62 µm, and 543.50±37.11 µm respectively. All 4 modalities of CCT 
 
measurements correlated closely with each other, with Pearson correlation coefficients 
 
ranging from 0.977 to 0.995. The mean differences (and upper/lower LoA) for CCT 
 
measurements were -0.05±6.77 µm (13.3/-13.3) between SD-OCT and Scheimpflug- 
 
Placido topographer, 4.38±3.79 µm (11.8/-3.1) between OLCR and SD-OCT, 
 
4.38±6.03 µm (16.2/-7.5) between OLCR and Scheimpflug-Placido topographer, 
 
13.20±6.46 µm (25.9/0.5) between USP and OLCR, 17.59±6.76 µm (30.8/4.3) 
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between USP and SD-OCT, and 17.58±8.13 µm (33.5/1.6) between USP and 
 
Scheimpflug-Placido topographer. Intra-examiner repeatability was excellent for all 
 
devices with ICCs>0.98.For most practical purposes, CCT measurements with the 
 
RTVue, Sirius and Lenstar can be used interchangeably. Although highly correlated, 
 
CCT measurement differences between USP and these 3 optical instruments can be 
 
significant depending on the clinical situation. rasound pachymetry (USP). 
 
 
 
 
 
 
Bao et al studied 70 subjects were enrolled in a prospective study.A single 
 
experienced ophthalmologist performed tests with each of the 4 instruments. 
 
Measurements were obtained in the right eye during the same session. The testing 
 
sequence of the NCSM was randomly selected. 
 
After performing noncontact examinations, the USP was performed to 
 
derive the CCT measurements. Intraoperator repeatability was analyzed 
 
using within-subject coefficient of variation and intraclass correlation 
 
coefficients. The agreement between NCSMs or NCSM and USP was 
 
assessed with Bland–Altman plots and 95% limits of agreement (LoA). 
 
Results: The mean CCT values measured by SP-3000P, EM-3000, SP-02, and USP 
 
were 513.66 6 33.14 mm, 529.12 6 33.22 mm, 549.06 6 40.27 mm, and 539.01 6 
 
35.73 mm, respectively. All coefficients of variation were ,1.3%, and the intraclass 
 
correlation coefficients were .0.95. There were statistically significant differences 
 
between any 2 devices as determined by CCT measurements.The mean difference 
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between paired comparisons was .9 mm. The 95% LoA ranges were broad, and the 
 
greatest 95% LoA was found to exist between SP-3000P and SP-02. 
 
 
 
Different methods of CCT measurement 
 
 
 
 
1. Kerasonix KSX-1000 ultrasound pachymeter 
 
Kerasonix KSX-1000 ultrasound pachymeter (DGH Technology, Exton, PA, USA) is 
 
a pachymeter which utilizes ultrasound energy to measure CCT. When the ultrasound 
 
energy is emitted from the probe tip, part of the energy is reflected back in the form of 
 
an echo. Depending on the velocity and time for energy to travel back to the receiver, 
 
the measurements are obtained. Measurements were made with the ultrasound 
 
velocity (acoustic index) set to 1,640 m/s. 
 
 
 
 
 
 
2. SL-OCT 
 
 
The SL-OCT (Heidelberg Engineering, Heidelberg, Germany) employs an internal, 
 
short coherent, infrared light source (super-luminescent light emitting diode) with a 
 
central wavelength approximately 1,310 nm. The SL-OCT is capable of 15 mm scan 
 
sizes with a scan depth of 7 mm. The lateral optical resolution capacity is less than 
 
100 μm and the lateral digitalized resolution capacity is 75 μm. The axial resolution 
 
capacity is less than 25 μm for optical resolution and 10 μm for digitalized resolution. 
 
The slit-beam produces a reflex that appears on both the outer and inner corneal 
 
surface as well as a sharp reflex beam through the anterior chamber. Scans were saved 
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and analyzed for CCT via the Heidelberg Eye Explorer (HEYEX) SL-OCT 
 
(Heidelberg Engineering) viewing software. 
 
 
 
 
 
3. The Konan Noncon Robo Pachy 
 
 
The Konan Noncon Robo Pachy (Konan Medical Corporation, Fairlawn, NJ, USA) is 
 
comprised of a non-contact microscope and camera. This device obtains a specular 
 
image of the corneal endothelium and also measures the corneal thickness. Subjects 
 
were positioned to focus on fixation target, and the corneal image was captured using 
 
the Noncon Robo specular microscope. The KSS-300 Image Storage System was used 
 
to acquire and save the image and subsequently analyze the CCT. 
 
 
4. Orbscan II 
 
 
Orbscan II (Bausch and Lomb, Rochester, NY, USA) analyzes the reflected images 
 
from multiple concentric rings which are projected on the anterior surface of the 
 
cornea. It has a high-resolution video camera which captures multiple light slits 
 
projected through the cornea similarly as seen during slit-lamp examination. The 
 
instrument’s software analyzes multiple data points per slit and calculates the corneal 
 
thickness. The anterior and posterior corneal surfaces were automatically detected 
 
with the system software. Once the images were recorded, calculations of the CCT 
 
were performed. The final reading was automatically adjusted using an acoustic 
 
correction factor (AF) of 0.92, as recommended by the manufacturer. 
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Changes in corneal thickness in diabetes 
 
 
Changes in corneal thickness have been well documented in diabetics(1), (2), (3), (4), 
 
(5), (6),(7),(8),(9),(10),(11), (12) Most studies have shown increased corneal thickness 
 
in diabetics as compared to non-diabetics..(1), (2), (3), (4), (5), (6),(7),(8),(9), (12) 
 
whreas few otner studies have shoen no change(ref) or decrease(REF) corneal 
 
thickness in diabetivs Corneal endothelial changes and metabolic factors affecting the 
 
corneal stromal hydration have been postulated as the cause for the increased corneal 
 
thickness. 
 
 
 
 
 
Studies showing increase in CCT in diabetics 
 
 
 
 
Abdul ghani et al (1) did a study to find correlation between CCT and diabetes in 
 
Sudanese Patients .They found that diabetic patients had an increased CCT when 
 
compared with non-diabetic patients. It was a cross-sectional study conducted in the 
 
Khartoum . 160 subjects were studied. An ultrasound pachymeter was used to 
 
measure CCT. The sample was divided into two groups, 80 were non-diabetic 
 
subjects, and 80 were diabetic patients .The average central corneal thickness in 
 
diabetic patients was 541.61± 22.92 microns with a range between 513 - 586. The 
48 
 
 
average CCT found in non-diabetic patients was 518.41 ± 34.09 microns with range of 
 
448 - 555. The increase in central corneal thickness found in diabetic patients 
 
compared to non-diabetic patients was statistically significant (p<0.005). Although 
 
there was CCT increase with increase of the duration of diabetes, it was not 
 
statistically significant. No statistically significant difference was shown between type 
 
1 and type 2 diabetes.. 
 
 
 
 
 
N. Busted et al (2) did a study where he made clinical observations on the corneal 
 
thickness and the corneal endothelium in diabetes mellitus on 81 insulin-dependent 
 
diabetic outpatients. 
 
The comeal thickness was measured by pachometry and the corneal endothelium was 
 
photographed by specular microscopy The corneal thickness of a normal group, 
 
diabetics without and with proliferative retinopathy was 0-527±0 028, 0-544±0-028, 
 
and 0-566+0 027 mm, respectively (2p<001). Specular photomicrographs showed 
 
minute folds in the endothelial layer in 13 of the diabetics versus 1 of the normal 
 
group (2p<0-01). 
 
 
 
 
 
Ozdamar et al(3) did a study to evaluate the association of central corneal thickness 
 
(CCT) with diabetes mellitus and compare it with age and sex-matched healthy 
 
controls. This study included 245 eyes of 245 subjects (one eye per subject). One 
 
hundred diabetic patients constituted the study group and 145 were healthy 
 
controls.They found that the central cornea of diabetic patients is thicker when 
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compared with nondiabetic patients. Thicker central cornea associated with diabetes 
 
mellitus should be taken into consideration while obtaining accurate intraocular 
 
pressure measurements in diabetics. The study group was subdivided into 3 
 
subgroups: subgroup 1 (no diabetic retinopathy), subgroup 2 (nonproliferative diabetic 
 
retinopathy), and subgroup 3 (proliferative diabetic retinopathy). CCT was determined 
 
with ultrasonic pachymeter. None of the patients had glaucoma, retinal laser 
 
treatment, and history of ocular surgery. Statistical analyses were performed by 
 
analysis of variance and Kruskall-Wallis tests. Correlation analysis was performed to 
 
assess the association between disease duration and glycosylated hemoglobin levels 
 
among subgroups.Demographic characteristics of study and control groups were 
 
similar (P>0.05). The mean CCT was significantly greater in study group (564±30 
 
μm) compared with control group (538±35 μm) (P=0.001). In addition, mean CCT 
 
was found to be greater in subgroup 3 (582±23 μm) compared with subgroups 1 
 
(565±32 μm) and 2 (558±31 μm); but the difference did not reach statistical 
 
significance (P=0.056). Also, there was no significant correlation in respect to the 
 
level of glycosylated hemoglobin and disease duration among the subgroups. 
 
 
 
 
 
 
Claramonte et al (4) did a study on 1000 patients to prove the existence of a 
 
correlation between CCT and diabetes. They found that diabetic patients had 
 
an increased CCT when compared with normal individuals. 
 
Ultrasound pachymetry was used. The sample was divided into two groups of 
 
patients: 953 of them were non-diabetic patients, and 47 were diabetic patients.The 
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average central corneal thickness in diabetic patients was 571.96 ± 26.81 microns with 
 
a range between 514 and 626. The average central corneal thickness found in non- 
 
diabetic patients was 544.89 ± 35.36 microns with range of 448 to 649. The increase 
 
in central corneal thickness found in diabetic patients compared to non-diabetic 
 
patients was statistically significant (p<0.001). 
 
 
 
 
 
Stor Paulsen et al (5) did a study to investigate corneal endothelial cell density and 
 
morphology in type 2 diabetic patients and normals to relate potential differences to 
 
the glycaemic status. The diabetic patients had on average > 4 HbA1c tests performed 
 
(mean 4.1; range 2–14) with intervals of at least 3 months as a reflection of the long- 
 
term glycaemic status. Endothelial cell density, variation in endothelial cell size 
 
(CV), hexagonal cells percentage, and CCT were recorded. Type 2 diabetics did not 
 
differ from the non-diabetic control subjects with regards to endothelial cell density, 
 
hexagonality or variation in CV, but showed a significant hike in CCT (538 versus 
 
546 , p < 0.05). In the diabetic group, lower cell counts were associated with greater 
 
HbA1c values . The HbA1c did not have any impact on the CCT. Type II diabetes 
 
has no impact on corneal cell density or morphology in subjects with good glycaemic 
 
status. However, greater HbA1c was associated with lower endothelial cell density. 
 
CCT was significantly increased in the diabetics. 
 
 
 
 
 
 
Mehmet et al(7) compared central corneal thickness (CCT) values of patients 
 
with type II diabetes mellitus with those of healthy subjects, and evaluated the effect 
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of disease duration, severity of retinopathy, and HbA1c level on CCT. 126 
 
consecutive type II diabetic patients and 36 healthy subjects were included in the 
 
study. CCT was measured using the Orbscan II corneal topography. The effect of 
 
disease duration, retinopathy severity, and HbA1c level on CCT were evaluated. 
 
CCT was significantly higher in diabetic patients than in normal. 
 
Severity of retinopathy and disease duration had no effect on CCT. 
 
Diabetic patients with HbA1c levels > 7% had thicker corneas than patients with 
 
HbA1c levels < 7% (P = 0.021). 
 
 
 
 
 
Calvo Maroto et al (8) did a study to evaluate the differences in endothelial cell 
 
density (ECD) and central corneal thickness (CCT) between type II diabetic patients 
 
and age-matched healthy controls.This is a comparative study of 77 eyes of type II 
 
diabetic patients (33 males, 44 females) and 80 eyes of healthy subjects (42 males, and 
 
38 females) whose ages ranged from 38 to 56 years. The CCT was significantly higher 
 
and the ECD significantly lower in long-term diabetic patients (10 years + since 
 
diagnosis) when compared with short-term diabetic patients (<1 year since diagnosis) 
 
and controls (both p < 0.001). No significant differences in CCT (p = 0.30) and ECD 
 
(p = 0.31) were found between control groups. Multivariate analysis of variance 
 
indicated that there was a significant effect of the diabetes duration in CCT and ECD. 
 
In diabetic patients, a two-way analysis of variance showed that CCT was 
 
significantly different for a 7.5% HbA1c cut-off value, and ECD for both 7.0% and 
 
7.5% HbA1c cut-off values.Type II diabetes causes a significant alteration in corneal 
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structure and function in the long term. Our study seems to confirm the effect of 
 
diabetes duration and poor glycaemic control on CCT and ECD changes. 
 
 
 
 
 
 
 
Su et al (12) did a study on Asian population to find an association between central 
 
corneal thickness (CCT) and potential systemic and ocular factors affecting CCT. 
 
They found that there was an association between CCT and higher IOP, longer axial 
 
length, greater radius of corneal curvature, higher BMI, metabolic syndrome, and 
 
chronic kidney disease. 
 
 
It was a cross-sectional study on a population of a total of 3,280 adults of Malay 
 
ethnicity living in Singapore .They underwent a standardized interview , ocular and 
 
systemic examination at a centralized study clinic. Ultrasound pachymeter was used 
 
to measure CCT. Blood samples were examined to determine serum glucose, 
 
cholesterol, and triglyceride levels, and urine samples to determine glomerular 
 
filtration rate. CCT was normally distributed with a mean of 541.2 microns in the right 
 
eye. While controlling for age and gender,CCT was greater in individuals with higher 
 
body mass index (BMI) (P < .038), greater intraocular pressure(IOP) (P < .001), 
 
greater axial length (P <.005), and greater radius of corneal curvature (P < .001). 
 
Individuals with CKD (P _ 0.012) and metabolic syndrome (P < .001) also had greater 
 
CCT. 
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Studies showing no change in CCT 
 
Choo M M et al3 compared corneal endothelial structure and central corneal 
 
thickness (CCT) between type II diabetics and non-diabetic control patients. It was 
 
found that there was no difference in CCT between the two groups. It was a hospital- 
 
based, observational study.200 eyes (from 100 type II diabetic patients and 100 
 
controls) were included.Specular microscopy were used to measure endothelial cell 
 
density, size, coefficient of variation in cell area, hexagonality and pachymetry was 
 
used to measure corneal thickness. Pearson correlation tests were used to evaluate 
 
correlations between corneal findings and diabetic status such as duration of diabetes, 
 
haemoglobin A1c (HbA1c) level and severity of diabetic retinopathy.They found that 
 
endothelial cell density in the diabetic group (2541.6± 516.4 cells/mm2) was 
 
significantly lower than that in the control group (2660.1± 515.5 cells/mm2, 
 
<0.05).The average size of endothelial cells, standard deviation (SD) of cell size and 
 
coefficient of variation (CV) of cell area were all significantly higher in diabetics. 
 
Hexagonality was significantly lower in diabetics (41.1% ± 19.6% ) compared to 
 
nondiabetics (45.2%± 20.6%). CCT was higher in diabetics but not significant ( 
 
>0.05). Duration of diabetes, HbA1c level and severity of diabetic retinopathy were 
 
not significantly correlated with corneal endothelial findings.Hence they concluded 
 
that Type II diabetes causes a significant alteration in the state of the cornea including 
 
reduction in endothelial cell density and increased pleomorphism and polymegathism. 
 
However, Central corneal thickness is unaffected. 
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Studies showing decrease in corneal thickness in diabetics 
 
Mc Namara et al (11) assessed corneal structure and the effects of acute 
 
hyperglycemia on corneal function in subjects with type 1 diabetes. In addition to 
 
differences in baseline corneal structure, diabetic subjects showed less corneal 
 
swelling and reduced corneal recovery' from hypoxia than did control subjects. During 
 
acute hyperglycemia, corneal swelling was less than during euglycemia in diabetic 
 
subjects, which suggests that hyperglycemia affected corneal hydration control. 
 
Twenty-one diabetic and 21 nondiabetic volunteers of similar age were recruited. 
 
Baseline measurements of intraocular pressure GOP), corneal thickness (CT), corneal 
 
autofluorescence (CAF), corneal sensitivity (CST), central and temporal endothelial 
 
cell density (DenC and DenT), and coefficient of variation in cell area (CVC and 
 
CVT) were taken. Corneal edema was induced, and the percent recovery per hour 
 
(PRPH) from hypoxic edema and endothelial permeability to fluorescein were 
 
determined. These procedures were done twice in the diabetic subjects 
 
under controlled euglycemic (EG) and hyperglycemic (HG) conditions, and once in 
 
control subjects while they were fasting. Substantial differences in baseline 
 
measurements were found for IOP, CT, CAF, CST, DenC, and CVT. The mean ± SE 
 
corneal swelling in the HG diabetic subjects (51.6 ± 2.3 /u,m) was less 
 
when compared to the swelling in the EG diabetic subjects (56.2 ± 1.87 fim, P = 0.05) 
 
and the control subjects (58.9 ± 1.56 jam, P = 0.011). During euglycemia, the mean ± 
 
SE PRPH was less in diabetic subjects than in control subjects (65.0 ± 3.20 versus 
 
73.8 ± 1.81%/hour, P = 0.02) but did not differ in diabetic subjects under EG and HG 
 
conditions (65.0 ± 3.20 versus 67.7 ± 3.1%/hour, P = 0.56). No significant differences 
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were noted between groups in endothelial permeability. 
 
.Hence we wish to look at any possible variation in thickness during hyper and 
 
euglycemic state which could be due to short term functional changes in the 
 
endothelium induced by hyperglycemia. 
 
 
 
 
Most of the studies have looked into diabetic changes in the cornea over time 
 
However there are no studies which have looked into these changes in human eyes 
 
with variation in blood sugar - euglycemic and hyperglycaemic state. 
 
 
 
Corneal thickness and duration of diabetes 
 
 
Duration of diabetes and type of diabetes correlation with CCT has been studied. 
 
 
Yasser et al (1)did a study on 160 Sudanese patients to find any correlation between 
 
change in CCT with duration of diabetes using ultrasound pachymetry. He divided the 
 
subjects into 3 subgroups .The mean CCT of diabetic patients for less than 5 years 
 
duration was 532.86 ±24.17, for patients with duration 5-10 years the mean CCT was 
 
544.56 ±22.70, and 546.87 ±20.38 for more than 10 years duration. 
 
Although there was an increase in central corneal thickness with increase duration of 
 
diabetes, it was not statistically significant (P=0.072). 
 
 
 
 
Choo et al (10) who did a study in Malaysia in 200 eyes using a non-contact 
 
Topcon SP3000P (Topcon Corp, Japan) also concluded that there was no significant 
 
correlation between CCT and duration of diabetes. 
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Corneal thickness and severity of retinopathy 
 
 
There were studies which looked into correlation between severity of diabetic 
 
retinopathy and CCT. Studies by Yesim et al(9) , Choo et al (10) and Mehmet et al 
 
(7)have shown no relation between the occurrence or severity of retinopathy with the 
 
CCT . However few other studies have shown increased CCT with worsening 
 
severity of the retinopathy. Hence we did not include severity of diabetic retinopathy 
 
as an exclusion criteria. 
 
 
 
 
 
Other factors altering CCT 
 
 
 
 
 
The Tajimi Study (79) obtained CCT measurement from 2868 persons who were 
 
40years and above from the population of Tajimi city of Japan and described the 
 
relationship between CCT and other factors such as age, height, weight, diastolic 
 
blood pressure,systolic pressure, intraocular pressure and corneal curvature.The 
 
multiple regression analysis showed that only gender , intraocular pressure and 
 
corneal curvature were significantly (P<0.011) associated with CCT 
 
 
 
 
 
 
The Central India eye and medical study had CCT measurement data on 9370 
 
(99.4%) eyes. By multiple regression analysis, CCT was associated significantly with 
 
younger age (P<0.001), male gender (P<0.001), higher body mass index (P = 0.006), 
 
lower corneal refractive power (P<0.001), deeper anterior chamber (P = 0.02), thicker 
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lens (P = 0.02), and shorter axial length (P = 0.006). Central corneal thickness was not 
 
associated significantly with refractive error (P = 0.54) or cylindrical refractive error 
 
(P = 0.20). If eyes with a corneal refractive power of 45 or more diopters were 
 
excluded, the relationship between CCT and axial length was no longer statistically 
 
significant (P>0.05), whereas all other relationships remained significant. Intraocular 
 
pressure readings increased significantly (P<0.001) with both higher CCT and higher 
 
corneal refractive power. (77) Most of the studies have looked into diabetic changes in 
 
the cornea over time. 
 
 
However there are no studies which have looked into these changes in human eyes 
 
with variation in blood sugar - euglycemic and hyperglycaemic state. 
 
 
 
 
 
CCT change in same diabetic patient before and after achieving 
good glycemic  control 
 
 
 
 
 
Unlike previous studies which compared CCT in diabetic patients and in control 
 
groups, Yesim Atley (9) et al did a study on central corneal thickness (CCT) in 
 
diabetic patients and its relationship with glycemic control (HbA1c levels). Single - 
 
centre, prospective, clinical trial with a mean of 6 - month follow - up examination. 
 
We included 52 patients with type 2 diabetes mellitus (DM) whose HbA1c levels were 
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above 7% , indicating poor glycemic control. Sex of patients, and duration of DM 
 
were recorded. CCT was determined with ultrasound pachymeter. Each CCT 
 
measurement was the mean of 3 pachymeter readings. Then the patients were treated 
 
by the endocrinology clinic. When glycemic control was achieved ( HbA1c <7% ), 
 
CCT measurements were recorded again. HbA1c and CCT before and after treatment 
 
were compared.Mean CCT before treatment was 552. 30 ± 29.26 πm, and mean 
 
HbA1c was (9. 36 ±1. 79 )% . Mean CCT after treatment was 542. 36 ±27. 20 πm, and 
 
mean HbA1c was (6. 45±0. 70)% . The difference between these two values was 
 
statistically significant (P = 0. 0001, paired t test).Even though mean hyperglycemic 
 
and euglycemic CCT measurements were in normal range, CCT decreases 
 
significantly by lowering HbA1c level ( good glycemic control ). Therefore, glycemic 
 
status (HbA1c) should be considered when examining the eye of diabetic patients. 
 
 
 
 
 
 
 
 
 
Hence we wished to look at any possible variation in thickness during hyper and 
 
euglycemic state which could be due to short term functional changes in the 
 
endothelium induced by hyperglycemia. 
 
 
 
 
 
 
Corneal changes during induced hyperglycemia and euglycemia 
 
 
There was one study Nancy A. McNamara et al (11) which looked for corneal 
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changes during induced hyperglycemia and euglycemia. But in this study 
 
experimental hypoxia was induced and changes in cornea during this hypoxia were 
 
recorded. They found that diabetic individuals showed less corneal swelling and 
 
reduced corneal 
 
 
recovery from hypoxia than did control subjects. During acute hyperglycemia, 
 
corneal swelling was less than during euglycemia in diabetic subjects, which suggests 
 
that hyperglycemia affected corneal hydration control. 
 
 
We wished to look at the natural history in real life situation in our clinic in diabetic 
 
patients the CCT changes in hyperglycemic and euglycemic states. 
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MATERIALS AND METHODS 
 
 
 
Study Design 
 
This is a cross sectional observational study 
 
 
 
 
 
 
Study Population 
 
Subjects were chosen from among those patients who had come for a medical check up to 
 
the outpatient department of Low Cost Effective Care Unit (LCECU), the community care 
 
centre situated in the same campus as the Department of Ophthalmology. Patients diagnosed 
 
as diabetics by the treating physician in LCECU and sent to the lab for post-prandial  
 
blood sugar measurements fulfilling the inclusion and exclusion criteria were recruited  
 
into the study 
 
 
 
 
 
 
Duration of study 
 
The study was conducted from November 2015 to July 2016 
 
 
 
 
 
 
Definition of hyperglycemic and euglycemic states 
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Hyperglcemic state – Post prandial blood sugars ≥ 200 mg/dl. 
 
Euglycemic state – Post prandial blood sugars < 200mg/dl along with minimum 50 mg/dl 
 
reduction of post prandial blood sugars as compared to their hyperglycemic state 
 
 
 
 
Inclusion Criteria 
 
          Diabetic patients in hyperglycemic state 
 
Exclusion Criteria 
 
1. Patients with serum creatinine >1.2mg/dl and / or urine microalbumin > 30mcg/min 
 
2. Patients in whom optical biometry is not possible 
 
3. Patients who have undergone previous ocular surgery 
 
4. Patients who have worn rigid contact lenses during the month prior to ophthalmic 
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evaluation and soft contact lenses seven days before 
 
 
5. Patients with any corneal pathology (degenerations, keratoconus, collagen–related 
 
disorders, glaucoma, intra- ocular inflammation, ocular surface disorders ) including 
 
corneal oedema 
 
6. Patients with uveitis 
 
7. Patients using topical eye drops 
 
8. Patients who have undergone procedures such as laser photocoagulation within less 
 
than 1 month 
 
9. Patients less than 18 years of age 
 
 
 
 
 
 
Ethics Committee Approval 
 
Once the study proposal was made, it was put forward to the Institutional Research 
 
Board. After approval from the ethics committee was obtained, the study was 
 
initiated. 
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Sample Size Calculation 
 
Sample size calculation was based on primary outcome variable - change in central 
 
corneal thickness (CCT) in the hyperglycemic and euglycemic state. 
 
Sample size calculation was based on a previous study from Turkey by Yesim et al 
 
who studied 52 diabetic patients. They found that the mean CCT before treatment 
 
was 552. 30 ± 29.26 µm, and mean HbA1c was (9. 36 ±1. 79 ). The mean CCT after 
 
treatment was 542. 36 ±27. 20 µm, and mean HbA1c was (6. 45±0. 70) . The 
 
difference between the two CCT values was statistically significant (P = 0. 0001) and 
 
was found to be 10 µm. Based on this, sample size of 90 was calculated to be 
 
required to detect this change of 10 um, assuming a standard deviation of 29, a power 
 
of 80 % and a significance level of 1%. 
 
 
The assumptions and resulting sample size calculation are shown below: 
 
 
 
 
Primary outcome variable = change in central corneal thickness, a continuous variable 
 
summarized by means 
 
Mean difference = 10 
 
Standard deviation = 29 
 
Significance level = 1% 
 
Power = 80% 
 
Total sample size = 90 
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Methodology 
 
All diabetic patients undergoing blood sugar measurements whose post prandial blood sugar 
 
levels were  more than 200mg/dl (hyperglycemic state) were screened by the principal 
 
investigator for the study and were enrolled into the study if they satisfied the inclusion 
and 
 
exclusion criteria after informed consent. Within half an hour of the blood sugar 
 
measurement , the CCT measurement was done. 
 
 
 
 
CCT was measured using optical biometer, Nidek AL scan (Nidek Co, Ltd, 
Gamagori, 
 
Japan) by the optometrist posted in the investigation room. 
 
 
 
 
As is the routinely followed management protocol / schedule, these patients were called 
for 
 
repeat fasting and post prandial blood sugar estimations at 1 month after changes if any in 
the 
 
anti-diabetic medications were advised by the treating physician. 
 
 
 
 
Subjects were reviewed after 1 month and corneal thickness measured as described above. 
 
 
 
 
The CCT values of those patients achieving euglycemic state ( post prandial blood sugars  
 
< 200mg/dl along with a minimum drop in blood sugar levels of 50mg /dl from the  
 
Previous hyperglycemic state) were taken for analysis. If the patients fail to achieve the  
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above criteria at 1 month visit, CCT measurements were repeated at the next month follow 
up and included for analysis if the patient achieved the required criteria within the study 
period. The right eye of patients was taken for analysis. If the right eye did not fit the 
inclusion and exclusion criteria, but the left eye fulfilled the criteria, the left eye was taken 
for analysis. 
Flow chart 
 
Patients diagnosed as diabetics by the treating physician in LCECU and 
 
sent to the lab for post prandial blood sugar measurements were screened. 
 
Those fulfilling the inclusion and exclusion criteria were recruited into the 
 
study after an informed consent 
 
 
 
 
 
 
 
The optometrist performed all CCT measurements using optical biometer within 
 
half an hour of post prandial blood sugars 
 
 
 
 
 
Subjects were reviewed after 1 month and CCT measured 
 
 
 
 
 
If the patients who failed to achieve the above criteria at 1 month visit, CCT 
 
measurements was repeated at the next month/ subsequent follow up and 
 
included for analysis if the patient achieved the required criteria within the study 
 
 
 
 
 
The right eye of patients was taken for analysis. 
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Data Collection 
 
Data was collected in a questionnaire (enclosure) which was implemented by the 
 
primary investigator. 
 
 
 
 
Statistical analysis 
 
The quantitative variables were measured using mean and standard deviation and 
 
qualitative variables were measured using frequency and percentage. Paired t- test was 
 
used to compare mean changes in CCT between hyperglycemic and euglycemic states. 
 
Association between changes in corneal thickness and other study variables were 
 
assessed using independent sample t-test or Chi – square test, as appropriate. Pearson 
 
correlation coefficient were calculated to assess the relationship between CCT and 
 
post prandial blood sugar levels 
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RESULTS 
 
 
 
A total of 226 diabetic patients (226 eyes) who were hyperglycemic were evaluated 
 
between November 2015 to July 2016. Of these, euglycemia at 1 month as defined in 
 
the methodology was achieved in 89 eyes. 24 patients were lost to follow up at 1 
 
month and the rest did not achieve euglycemia at 1 month. Among those who did not 
 
achieve euglycemia at 1 month, euglycemia was achieved in a few of them at 3 
 
months’ time (16 patients); rest of them either failed to achieve euglycemia during the 
 
study period or lost to follow up. 
 
 
 
 
 
 
Table 1.Baseline characteristics of the study patients 
 
Total number of patients who achieved 
 
euglycemia 
89 
Number of males 23 
Number of females 66 
Average age (years) 52.39 
Range of age (years) 26-75 
Average duration of diabetes (years) 7.4 
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CCT in hyperglycemic state and euglycemic states: 
 
The mean CCT of the eighty nine patients in hyperglycemic state was 501.38 ± 25.28 
 
microns and 502.20 ± 25.05 microns in the euglycemic state as shown in table 2. 
 
There was no significant difference in the central corneal thickness in hyperglycemic 
 
state in comparison to euglycemic state (p=0.167) 
 
 
 
 
Table2. CCT in hyperglycemic and euglycemic states 
 
 
 
 
Glycemic status Mean(microns) ± SD Range (microns) 
Hyperglycemia 501.38± 25.28 444 to 560 
Euglycemia 502.20 ± 25.05 447 to 569 
P=0.167 
 
 
 
 
Analysis of relationship between change in CCT and the amount of blood 
sugar level reduction: 
 
 
Since overall we did not find any change in the CCT between hyperglycemic and 
 
euglycemic blood sugar levels, we divided the patients into 3 subgroups according to 
 
the amount of reduction in the blood sugars and the CCT change in each of the three 
 
subgroups.1
st 
subgroup consisted of patients who had a drop in blood sugars ranging 
 
50-100mg/dl, 2
nd 
subgroup (101-200mg/dl) and 3
rd 
subgroup (200-320mg/dl). 
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Amount of 
reduction in 
blood sugar 
No. of 
patients 
CCT (microns)in 
HS* 
(Mean±SD,Range) 
CCT (microns)in 
ES ** 
(Mean±SD, Range) 
50-100 44 497.91 ± 24.20 
(456 to 545) 
497.86 ± 23.73 
(458 to 546) 
101-200 38 507.10 ± 25.31 
(448 to 560) 
508.763 ± 25.23 
(454 to 569) 
200-320 7 492.14 ± 28.71 
(444 to 522) 
493.86 ± 27.35 
(447 to 520 
 
C
C
T 
(m
i
o
n
s)
 
 
CCT did not show any change (table 3, figure1.) in the three subgroups. 
 
 
 
 Table3. CCT change with the amount of blood sugar level reduction 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Hyperglycemic state, **Euglycemic state 
 
 
 
 
515 
   
510 
 
505 
 
500 
 
495 
 
490 
 
485 
 
480 
1 2 3 
Series1              497.91                           507.1                           
492.14 Series2              497.86                          508.76                          
493.86 
 
 
Blue column-hyperglycemic state, Red column- euglycemic state 
X axis -1=50-100mg/dl, 2=101-200mg/dl, 3=201-320mg/dl 
Figure 1. CCT change in subgroups divided as per duration of diabetes 
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Duration of 
diabetes 
No. of 
patients 
CCT (microns )in HS* 
Mean ±SD,Range 
CCT (microns )in ES* 
Mean ±SD,Range 
<5yrs 29 500.21 ± 22.89 
 
(469 to 546) 
500± 22.84 
 
(462 to 555) 
5-10yrs 40 503.67 ± 25.21 
 
(444 to 543) 
504.65 ± 24.82 
 
(447 to 545) 
>10yrs 20 498.5 ± 29.33 
 
(448 to 560) 
500.5 ± 29.15 
 
(454 to 569) 
 
 
 
 
 
Analysis of change in CCT and duration of diabetes during hyperglycemic 
and euglycemic state 
 
 
 
 
 
The changes in CCT from hyperglycemic state to euglycemic state in patients 
 
according to the duration of diabetes is shown in table 4 and figure 2 
 
 
 
 
 
 
 
Table 4: CCT change in subgroups divided as per duration of diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Hyperglycemic state, **Euglycemic state 
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506 
505     
 504.65  
504 
503 
502 
501 
500 
500.5 
500 
499 
498 
497 
496 
495                              
1                                                    2                                                    
3 
Series1                      500.21                                          503.67                                           
498.5 Series2                         500                                             504.65                                           
500.5 
 
 
 
 
Blue column-hyperglycemic state, Red column- euglycemic state 
X axis -1=50-100mg/dl, 2=101-200mg/dl, 3=201-320mg/dl 
 
 
 
Figure 2 CCT change in subgroups divided as per duration of diabetes 
 
 
 
 
There was no significant difference in CCT according to the duration of diabetes. 
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Analysis of the relationship between CCT difference and post prandial blood  
sugar difference 
 
 
There was no correlation (table 5) between change in CCT and change in PPBS (r= 
 
0.148) (figure 2) 
 
 
 
 
Table 5 Correlation between CCT difference and PPBS difference 
 
 
 
 PPBS diff CCT diff 
 
 
PPBS 
diff 
 
 
 
 
CCT 
diff 
Pearson Correlation 1 .148 
Sig. (2-tailed)  .167 
N** 
 
Pearson Correlation 
89 
 
.148 
89 
 
1 
Sig. (2-tailed) .167  
N** 89 89 
*diff- difference, N**= Number of study patients 
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*X-axis represents the amount of reduction of blood sugars(two hour post prandial blood sugars) 
between hyperglycemic and euglycemic states 
 
Figure2: CCT difference versus PPBS difference between hyperglycemic and 
 
euglycemic state 
 
 
 
 
 
However when we looked at individual data we found that more patients (48 patients) 
 
showed an increase in CCT in euglycemic state compared to hyperglycaemic state. 33 
 
patients showed a decrease in CCT and 8 patients no change in CCT in euglycemic 
 
state as compared to hyperglycemic state (Table 6). 
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Table 6: Number of patients showing increased, decreased or no changein in CCT in 
 
euglycemic and hyperglycemic states 
 
 
 
 
Total number of patients 89 
No. of patients showing increase in CCT 
 
on achieving euglycemic state 
48 
No. of patients showing decrease in CCT 
 
on achieving euglycemic state 
33 
No. of patients showing no change in 
 
CCT on achieving euglycemic state 
8 
 
 
 
Among the 48 patients where there was an increase in CCT in euglycemia, 14 patients 
 
had an increase in CCT of more than 5 microns and the rest less than 5 microns. 
 
Data of these 14 patients is given in the table 7. 
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No. Age 
 
(yrs*) 
DM 
 
Duration(yrs*) 
PPBS 
 
(HG**) 
 
(mg/dl) 
CCT 
 
(HG**) 
 
(microns) 
PPBS- 
 
EG*** 
 
(mg/dl) 
CCT 
 
(EG***) 
 
(microns) 
PPBS 
 
diff**** 
CCT 
 
diff**** 
1. 49 6 251 539 189 545 62 6 
2. 44 12 245 472 178 478 67 6 
3. 49 2 336 484 196 490 140 6 
4. 45 5 293 530 143 536 150 6 
5. 60 30 289 448 137 454 152 6 
6. 64 5 250 492 171 499 79 7 
7. 44 15 324 510 164 517 160 7 
8. 38 7 426 507 198 514 228 7 
9. 43 8 305 482 156 490 149 8 
10. 50 12 305 470 181 479 124 9 
11. 53 3 303 546 166 555 137 9 
12. 68 15 251 560 99 569 152 9 
13. 61 10 252 500 144 511 108 11 
14. 54 9 316 506 196 521 120 15 
 
 
Table 7. Data of individuals (n=14) who showed an increase of >5microns in CCT in 
 
euglycemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
yrs*-years,HG**-hyperglycemic state, EG ***-euglycemic state, Diff****- difference 
 
In these patients also there was no relationship between the amount of drop in blood 
 
sugars and change in the CCT during hyperglycemic and euglycemic state. 
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No. Age Diabetes 
 
duration 
 
(yrs*) 
PPBS 
 
(HG**) 
 
(mg/dl) 
CCT 
 
(HG**) 
 
(microns) 
PPBS- 
 
EG*** 
 
(mg/dl) 
CCT 
 
(EG***) 
 
(microns 
PPBS 
 
diff**** 
CCT 
 
diff**** 
1 38 1 239 470 169 462 70 -8 
2 50 2 255 521 168 513 87 -8 
3 52 8 347 514 197 506 150 -8 
4 43 10 217 543 148 537 69 -6 
 
 
Among the 33 patients where there was a decrease in CCT in euglycemia, 4 patients 
 
had an decrease in CCT of less than 5 microns. Data of these patients is given in the 
 
table 8 
 
 
 
 
 
 
 
 
 
 
Table 8. Data of individuals (n=4) who showed an decrease of < 5microns in CCT in 
 
euglycemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
yrs*-years, HG**-hyperglycemic state, EG ***-euglycemic state, Diff****- difference 
 
In these individuals also there was no correlation with the amount of reduction in the 
 
blood sugars and the change in CCT during hyperglycaemic and euglycemic state. 
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DISCUSSION 
 
 
 
The euglycemic state in our study was defined as measured by 2 hour PPBS of < 
 
200mg/dl along with a drop of 50 mg/dl from the hyperglycemic state at 1 month. We 
 
included patients with drop in blood sugars of a minimum of 50 mg/dl along with 
 
blood sugar levels < 200mg/dl to avoid patients with minor changes in blood sugars, 
 
where in such small variations may not cause any detectable changes in the corneal 
 
parameters. We looked for changes at 1 month since that was the routine follow up 
 
protocol for diabetic patients to recheck blood sugars. 
 
 
 
 
 
We also excluded patients with renal disease as the fluid accumulation in these 
 
patients may lead to altered corneal hydration. However no literature is available on 
 
the corneal thickness being studied in diabetics with nephropathy as a separate group. 
 
 
 
 
 
The mean CCT in the 89 patients studied was 501.38± 25.28 microns in the 
 
hyperglycemic state and 502.20 ± 25.05 microns in the euglycemic state. There was 
 
no difference in the CCT between hyperglycemic and euglycemic state. 
 
 
There are few studies which have looked into corneal changes in hyperglycaemic and 
 
euglycemic state. Yesim et al (9) have studied CCT in hyperglycemic and euglycemic 
 
state in 52 diabetic patients and found that there was a significant reduction in CCT 
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when patients achieved euglycemia. However in these patients euglycemia was 
 
defined as HbA1c ≤ 7% and actual blood sugar values at the time that CCT was 
 
measured was not recorded. The average time to achieve euglycemia in the patients 
 
studied was 6 months (range4-8 months). It would be interesting to follow up patients 
 
who have taken longer duration to achieve euglycemia and check their CCT to see if 
 
CCT in these patients is different than those patients that we have studied at 1 month. 
 
. Mc. Namara et al (11) induced acute hyperglycemia in both diabetics and normals 
 
and assessed the changes in corneal parameters like corneal thickness, corneal 
 
autofluorescence , corneal swelling response (CSR), percent recovery per hour(PRPH) 
 
and endothelial permeability to fluorescein studied over 24 hours. They studied 
 
changes in corneal parameters when hypoxia was induced using contact lenses in 
 
euglycemic and hyperglycemic states among diabetic and non-diabetics. They did not 
 
address changes in CCT under non experimental/ natural course . They found that 
 
diabetics showed lower corneal swelling and decreased corneal recovery from hypoxic 
 
conditions as compared to normal. They also found that the swelling of cornea was 
 
lesser in acute hyperglycemic state as compared to euglycemic states in diabetics 
 
suggesting corneal hydration was affected by hyperglycemia. 
 
 
 
 
 
In our study corneal thickness was lower in diabetics as compared to the CCT 
 
documented in other studies. 
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Study CCT 
measurement 
method 
CCT in µm ( DM and Controls) 
Busted et al Haag- Streit 
pachymeter 
NPDR**-554 (N=81) PDR***-566 
Controls- 527 (N=49) 
Keoleian et al Specular microscope DM*-560 (N=14) Control- 560 (N=14) 
Schultz et al Specular microscope Type 1-540(N=31) 
Type 2- (530-540) (N=46), 
Controls -540 (type 1) 530-570 (type2 ) 
(N=76) 
Larsson et al Specular microscope type 1-(580) (N=49) 
type 2 (570) (N=60) 
Roszkowska 
et al 
Specular microscope type 1 -580 (N=30) 
type 2 -570 (N=45) 
type1controls-540 (N=62) 
type 2 controls-550 
Rosenberg et 
al 
Confocal microscope severe retinopathy -596 (N=23) 
control -527 N=9) 
Lee et al Ultrasound 
pachymetry 
 
DM*-588 (N=200) 
 
 
 
 
 
 
Table 9 – Other studies on corneal alterations in diabetics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DM*-Diabetic patients, NPDR**-Non proliferative diabetic retinopathy, PDR***-
Proliferative diabetic retinopathy 
 
 
 
 
The low CCT in our study could be explained by the variation in instrumentation used 
 
to measure corneal thickness. We used the non contact optical biometer whereas other 
 
studies have used ultrasound pachymetry or specular microscope to measure CCT. 
 
CCT values measured by non contact devices have been documented to be lower than 
 
conventional ultrasound pachymetry devices by 20-30microns depending on the 
 
devices used. Bao et al(90) .However optical biometry was chosen in our study since 
 
the measurements are operator independent compared to ultrasound pachymetry 
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which needs corneal contact and indentation which could lead to intra or inter 
 
observer variation.In an earlier study in our institute and a study in south indian 
 
population (Korah et al (80), Natarajan et al (67))using ultrasound pachymetry 
 
CCT in normals was around 530 microns. Accounting for variation in instrumentation 
 
technique.in measuring CCT ,the CCT measured among diabetics in our population 
 
would be similar or lesser than normals. CCT measurement using optical biometry in 
 
a control group of normal would be ideal for comparison .However this was not 
 
included in the scope of study as the aim of our study was to look for changes in 
 
corneal thickness in the same individuals with changing blood sugars rather than to 
 
determine the corneal thickness in diabetics as a whole. 
 
 
 
 
 
Since we did not find any variation in CCT in hyperglycemic and euglycemic state we 
 
analysed the data to see if CCT showed any change in those patients where there were 
 
larger reduction in blood sugar levels (.>200mg/dl) but found no association. We did 
 
not find any studies which have looked into amount of blood sugar variation and CCT. 
 
 
 
 
 
We also looked at possibility of duration of diabetes affecting the corneal responses to 
 
change in blood sugars. We sub analysed the data according to the duration of 
 
diabetes but found no difference short or long standing (>10years). Similarly some 
 
studies have shown no variation of CCT(10) with duration of diabetes whereas others 
 
have shown thicker corneas (1)with increased duration. 
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Most studies have not shown any changes (7), (9),(10), according to severity of 
 
retinopathy though some have reported variation of corneal thickness according to the 
 
grade of retinopathy. We did not assess retinopathy during the study . It is unlikely 
 
that this would have affected the results, However all patients seen in the LCECU are 
 
regularly screened for retinopathy as a part of their regular management protocol and 
 
appropriately managed for retinopathy if found. 
 
 
 
 
 
Studies such as Larsson et al(18) have shown that there is no variation in CCT 
 
according to the type of diabetes. Hence we included both Type 1 AND Type 2 
 
diabetics, 
 
 
 
 
 
Patients in our study were on insulin or oral medications for control of diabetes. 
 
Studies such as Yesim(9) et al have shown that there was no statistically significant 
 
difference in terms of the treatment modality (p=0.54) ( n=24patients taking insulin , 
 
n=28 patients taking oral antidiabetics). Hence the type of medications is unlikely to 
 
have affected our study results. 
82 
 
 
In summary, our study did not show any changes in corneal thickness between 
 
hyperglycaemic and euglycemic states (with euglycemia being recorded at 1 month 
 
interval). 
 
 
We propose that acute changes in blood sugars under normal conditions do not cause 
 
short term changes in CCT. However in conditions of stress or hypoxia (contact lens 
 
or surgical trauma induced), the cornea in hyperglycemic state may respond 
 
differently as compared to euglycemic state as noted by Mc Namara(11) et al who 
 
noted reduced corneal swelling but greater corneal recovery time in diabetics in 
 
hyperglycemic state as compared to euglycemic state. 
 
 
Short term effects on corneal swelling response and corneal recovery time during 
 
times of hypoxia and stress could have relevance clinically in patients scheduled for 
 
surgery or using regular contact lens which could cause changes in CCT under these 
 
conditions. 
 
 
 
 
 
Under normal non stress conditions, fluctuations of blood sugars or hyperglycemia are 
 
unlikely to cause short term variations in CCT. Hence routine checking of intra 
 
ocular pressure measurements is not likely to be affected by hyperglycemia. 
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CONCLUSIONS 
 
 
1. There was no difference in central corneal thickness in diabetics in 
 
hyperglycemic and euglycemic state achieved at 1 month. 
 
2. There was no correlation between change in blood sugar and change in central 
 
corneal thickness. 
 
3. Short term fluctuations (1 month) in blood sugars did not cause any change in 
 
CCT in diabetics . 
 
4. Routine IOP measurements are unlikely to be influenced by short term 
 
variations in blood sugars in diabetics. 
 
5. The patients included in the study were those without nephropathy. Possible 
 
metabolic changes and corneal responses to hydration could vary in these 
 
patients with fluid overload. The results of this study may not be applicable to 
 
this sub group of patients and needs to be studied further. 
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LIMITATIONS OF THE STUDY 
 
 
Comparison of euglycemia and hyperglycemia at 1 month interval was done as this 
 
was the interval at which diabetic patients were called for review to recheck the blood 
 
sugars. Since we were looking for acute/short term variation in CCT with changes in 
 
blood sugar levels, it would have been ideal to obtain continuous blood sugar values 
 
and corresponding CCT measurements. Recently continuous blood sugar monitoring 
 
has been possible using flash glucose monitoring system (Abbott Diabetes Care) 
 
However this was beyond our scope of study due to its prohibitive costs. Also a 
 
continuous CCT measuring device is not feasible. But looking at our data in this 
 
study , variations in CCT which would be of clinical significance is unlikely and 
 
hence repeated CCT measurement is probably not required. 
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APPENDIX A : PATIENT INFORMATION SHEET 
 
                                                             
 We are doing a study to look for any change in the thickness of cornea with change in 
blood sugar levels in diabetes patient. 
Diabetes mellitus affects various organs in the body including the eye. Various  corneal 
changes have been well described in diabetics . Various studies have shown that the cornea 
is usually thicker in diabetics. Corneal thickness measurements are necessary as variation in 
corneal thickness can lead to variation in the intraocular pressure measurements. Though 
studies have shown that the cornea is thicker in diabetics compared to normals, we have 
limited information as to whether the corneal thickness changes when sugar levels are 
normal compared to when sugar levels are high OR  if the corneal thickness changes occur  
gradually over time without any short term variation related to raised  blood sugar levels. So 
we wish to get this information by checking the corneal thickness (in the same patient)when 
the blood sugars are high and once it is controlled to normal levels.   
If you agree to participate in our study , we will do a  corneal thickness measurement of 
your eye in ophthalmology department in room number 40 within half an hour of post 
prandial blood sugar  measurement .Then when you come for follow up after 1 month we 
will repeat the measurement ( within half an hour of your blood sugar level being checked). 
The procedure of measuring the corneal thickness is not invasive and the actual 
measurement takes about two minutes. There will be no additional charges if you 
participate in the study . There will not be any additional risk for you by participating in the 
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study. Your participation in the study is voluntary and you are free to decide to withdraw 
permission to participate in the study. 
If you withdraw to participate, it will not affect you treatment in this hospital. The names or 
identity of the participants will not be disclosed or published. All the hospital records will 
be kept confidential. If you are interested about the results of the study it will be briefed to 
you .However your medical notes may be reviewed by people associated with the study 
without your additional permission, should you decide to participate in this study. 
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APPENDIX B : INFORMED CONSENT FORM FOR SUBJECTS 
 
 
 
 
 
Informed Consent form to participate in a research study  
 
Study Title: Study of  central corneal thickness (CCT) in diabetics in euglycemic and 
hyperglycemic states 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for 
the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I agree not to restrict the use of any data or results that arise from this study     
            provided such a use is only for scientific purpose(s). [  ] 
 
(iv)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
 
 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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APPENDIX C: CLINICAL RESEARCH PROFORMA 
 
Case No:                                                        Hospital No: 
 Age:                                                              Sex: Male/Female 
Occupation:                                                   Contact No: 
Address: 
Right / Left Eye 
Duration of diabetes 
 
Previous ocular  surgery                                                                                        Yes/No 
Use of  rigid contact lenses during the month prior to ophthalmic evaluation     Yes/No 
Use of soft contact lenses seven days prior to ophthalmic evaluation                 Yes/No 
Any corneal pathology 
                   Degenerations                                                                                   Yes/No 
                   Keratoconus                                                                                       Yes/No 
                   Collagen–related disorders                                                                 Yes/No 
                   Glaucoma                                                                                           Yes/No 
                   Intra- ocular inflammation                                                                 Yes/No 
                   Ocular surface disorders                                                                    Yes/No 
                   Corneal oedema                                                                                 Yes/No 
                  Others  ………………… 
Use of topical eye drops                                                                                       Yes/No 
Procedures such as laser photocoagulation within less than 1 month                  Yes/No 
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HYPERGLYCEMIC STATE 
Date, time  of 2hour PPBS:     _ _ / _ _ / 201_    ,    _ _ / _ _ am/pm      
2 hour Post prandial blood sugars (PPBS)  - ………. 
Time of CCT - _ _ /_ _ am/pm 
EUGLYCEMIC STATE 
Date, time  of 2hour PPBS:     _ _ / _ _ / 201_    ,    _ _ / _ _ am/pm      
2 hour Post prandial blood sugars (PPBS)  - ………. 
Time of CCT - _ _ /_ _ am/pm 
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HS1PPBS HS 1RE  CCT  ES  PPBS ES RE CCT ppbs diff cct diff 
229 522 176 519 53 -3 
241 531 121 534 120 3 
292 538 181 537 111 -1 
309 466 103 469 206 3 
316 515 152 514 164 -1 
218 485 149 484 69 -1 
250 487 114 484 136 -3 
307 490 193 488 114 -2 
201 494 104 493 97 -1 
250 509 194 506 56 -3 
362 465 190 468 172 3 
296 542 131 539 165 -3 
277 479 179 479 98 0 
288 478 163 477 125 -1 
349 512 153 511 196 -1 
217 543 148 537 69 -6 
300 493 155 495 145 2 
305 470 181 479 124 9 
256 478 176 480 80 2 
303 516 190 515 113 -1 
278 480 182 480 96 0 
254 483 154 483 100 0 
330 515 185 511 145 -4 
254 492 197 496 57 4 
336 484 196 490 140 6 
218 484 140 480 78 -4 
222 487 127 490 95 3 
387 444 171 447 216 3 
211 459 155 461 56 2 
319 520 200 521 119 1 
297 487 197 488 100 1 
239 470 169 462 70 -8 
316 506 196 521 120 15 
244 535 186 530 58 -5 
290 482 98 484 192 2 
363 484 171 485 192 1 
469 493 150 495 319 2 
245 472 178 478 67 6 
289 448 137 454 152 6 
233 545 175 546 58 1 
251 492 185 495 66 3 
235 520 124 516 111 -4 
256 510 189 511 67 1 
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229 507 169 509 60 2 
317 516 162 511 155 -5 
252 500 144 511 108 11 
265 456 175 458 90 2 
225 519 145 519 80 0 
235 471 151 474 84 3 
300 462 164 463 136 1 
230 512 145 516 85 4 
238 521 128 523 110 2 
265 484 180 482 85 -2 
214 499 131 499 83 0 
324 510 164 517 160 7 
216 489 122 491 94 2 
251 539 189 545 62 6 
240 496 158 492 82 -4 
272 483 172 483 100 0 
255 521 168 513 87 -8 
274 516 129 514 145 -2 
223 481 151 480 72 -1 
238 512 145 513 93 1 
245 501 102 501 143 0 
303 546 166 555 137 9 
250 492 171 499 79 7 
293 530 143 536 150 6 
220 481 146 477 74 -4 
339 492 130 494 209 2 
271 533 163 530 108 -3 
298 469 200 473 98 4 
250 480 181 484 69 4 
269 480 196 477 73 -3 
276 525 164 529 112 4 
251 560 99 569 152 9 
427 521 190 518 237 -3 
305 482 156 490 149 8 
347 514 197 506 150 -8 
426 507 198 514 228 7 
268 495 155 492 113 -3 
397 522 189 520 208 -2 
293 509 150 511 143 2 
275 495 190 492 85 -3 
377 541 186 540 191 -1 
232 541 147 542 85 1 
216 519 154 516 62 -3 
318 513 192 512 126 -1 
254 542 178 540 76 -2 
227 534 137 534 90 0 
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